Marisa Wexler, MS,  senior science writer—

Authorities in the European Union (EU) have agreed to review Kalvista Pharmaceuticals’ application requesting the approval of oral sebetralstat as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE). The company’s marketing authorization application (MAA) now will be reviewed by a committee of…

Astria Therapeutics is teaming up with Ypsomed, a Swiss-based company, to develop an autoinjector for its experimental treatment STAR-0215 for hereditary angioedema (HAE). “With STAR-0215’s profile, our goal is to develop a therapy that allows patients to choose an approach that works best for their lives with…

A single dose of the gene-editing therapy NTLA-2002 led to significant reductions in the number of swelling attacks among people with hereditary angioedema (HAE) in a Phase 2 clinical trial. NTLA-2002’s developer, Intellia Therapeutics, announced the study met its main goal, demonstrating that the investigative gene therapy…

The oral medication Orladeyo (berotralstat) is now approved in Peru as a prophylactic, or preventive, treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval from Peru’s General Directorate of Medicines, Supplies and Drugs comes just months after…

KalVista Pharmaceuticals has started a clinical trial to test the oral medication sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE), ages 2-11. The launch of KONFIDENT-KID (NCT06467084) came just a few weeks after KalVista asked the U.S. Food and…

Most hereditary angioedema (HAE) patients are able to take on-demand oral tablets of sebetralstat within 10 minutes of a swelling attack starting, and begin experiencing symptom relief within two hours, with complete resolution within about a day. That’s according to interim findings from an open-label extension Phase 3…

Genetic variants in the CC2D2B gene may affect disease severity in hereditary angioedema (HAE) types 1 and 2, according to a new study. “We demonstrated, on a large cohort of [people with HAE types 1 and 2], the importance of the CC2D2B gene as a disease-modifying factor,” the researchers…

The unusual case of a woman with drug-induced angioedema that led to a rare complication called acute compartment syndrome (ACS) in all four of her limbs was described in a recent report from Japan. ACS is a disorder in which the pressure within one of the body’s compartments —…

The once-daily oral therapy Orladeyo (berotralstat) has been approved in Brazil to prevent swelling attacks in people, 12 and older, with hereditary angioedema (HAE). The approval by the Brazilian Health Regulatory Agency (ANVISA) makes Orladeyo the first oral prophylactic (preventive) therapy authorized for HAE patients in the country.

Treatment with the experimental under-the-skin injection therapy STAR-0215 reduced the rates of monthly swelling attacks by more than 90% in people with hereditary angioedema (HAE) in a small early clinical trial. That’s according to new data announced by developer Astria Therapeutics, which further showed that HAE attacks…